Celltrion Receives Approval for Phase 3 Clinical Trial Plan on European Interchangeability of Uplizna

[Asia Economy Reporter Minji Lee] Celltrion announced on the 4th that it has received approval for a Phase 3 clinical trial plan comparing the pharmacokinetics and efficacy of Uplima (CT-P17, Humira biosimilar) and Humira in patients with severe plaque psoriasis.

The company explained, "In addition to the product approval for all indications approved for Humira, by further proving interchangeability, we expect to increase market share in the large U.S. market."